JGC
IONS icon

J. Goldman & Co’s Ionis Pharmaceuticals IONS Stock Holding History

J. Goldman & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,000
Closed -$7.51M – 539
2025
Q2 		$7.51M Buy
+190,000
New +$6.22M 0.18% 157
2024
Q4 		– Sell
-90,800
Closed -$3.64M – 541
2024
Q3 		$3.64M Sell
90,800
-54,200
-37% -$2.52M 0.1% 193
2024
Q2 		$6.91M Buy
+145,000
New +$5.95M 0.2% 141

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

J. Goldman & Co's IONS Position: Q2 2026 in Review

J. Goldman & Co reduced its Ionis Pharmaceuticals (IONS) stake by 83% in Q2 2026, selling an estimated $14.7M and leaving 40,366 shares worth $3.2M. The position accounts for 0.08% of the portfolio, ranked #273.

J. Goldman & Co first reported a position in IONS in Q1 2024 and has held it in 10 quarters since. The position peaked at $24.4M in Q3 2024. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • J. Goldman & Co held 40,366 shares of Ionis Pharmaceuticals worth $3.2M as of Q2 2026.
  • J. Goldman & Co sold 194,894 Ionis Pharmaceuticals shares in Q2 2026, an estimated $14.7M.
  • Ionis Pharmaceuticals made up 0.08% of J. Goldman & Co's portfolio in Q2 2026, its #273 holding.
  • J. Goldman & Co first reported a position in Ionis Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • J. Goldman & Co's Ionis Pharmaceuticals position peaked at $24.4M in Q3 2024.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.